Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
Upturn AI SWOT - About
Putnam Biorevolution ETF (SYNB)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: SYNB (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type ETF | Historic Profit 5.89% | Avg. Invested days 61 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  4.0 | ETF Returns Performance  2.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Volume (30-day avg) - | Beta - | 52 Weeks Range 24.57 - 33.00 | Updated Date 06/29/2025 |
52 Weeks Range 24.57 - 33.00 | Updated Date 06/29/2025 |
Upturn AI SWOT
Putnam Biorevolution ETF
ETF Overview
Overview
The Putnam BioRevolution ETF (symbol: SYNB) focuses on companies expected to benefit from advancements in biotechnology, genomics, and related fields, targeting growth through innovative healthcare solutions and technologies.
Reputation and Reliability
Putnam Investments is a well-established investment management firm with a long history in the industry, known for its diverse range of investment products and research capabilities.
Management Expertise
Putnam's management team consists of experienced professionals with deep knowledge of the healthcare and biotechnology sectors.
Investment Objective
Goal
The investment goal of the Putnam BioRevolution ETF is to seek capital appreciation by investing in companies involved in the 'BioRevolution'.
Investment Approach and Strategy
Strategy: The ETF does not track a specific index. It is actively managed and employs a thematic approach, focusing on companies expected to benefit from breakthroughs in areas such as genomics, personalized medicine, and synthetic biology.
Composition The ETF holds stocks primarily of companies engaged in biotechnological activities.
Market Position
Market Share: Data not readily available to provide an accurate market share.
Total Net Assets (AUM): 19320000
Competitors
Key Competitors
- ARK Genomic Revolution ETF (ARKG)
- iShares Biotechnology ETF (IBB)
- SPDR S&P Biotech ETF (XBI)
Competitive Landscape
The ETF market for biotechnology and genomics is competitive, with several established players. SYNB, being a newer and smaller ETF, needs to differentiate itself through superior stock selection or a more specific investment focus. ARKG is known for its aggressive growth strategy, while IBB and XBI offer broader, more diversified exposure to the biotechnology sector.
Financial Performance
Historical Performance: Historical performance data needs to be sourced from reputable financial data providers.
Benchmark Comparison: Benchmark comparison data needs to be sourced from reputable financial data providers.
Expense Ratio: 0.59
Liquidity
Average Trading Volume
The Putnam BioRevolution ETF's average trading volume is relatively low compared to its competitors, indicating moderate liquidity.
Bid-Ask Spread
The bid-ask spread for SYNB can vary depending on market conditions, but tends to be wider than more liquid ETFs.
Market Dynamics
Market Environment Factors
The ETF's performance is influenced by factors such as regulatory changes in the healthcare industry, advancements in biotechnology, and overall market sentiment towards growth stocks.
Growth Trajectory
The growth trajectory depends on the fund's ability to identify and capitalize on emerging trends within the BioRevolution space. Changes to strategy and holdings would be found in the fund's regular disclosure.
Moat and Competitive Advantages
Competitive Edge
SYNB's active management approach, which allows for dynamic stock selection based on emerging trends and opportunities within the 'BioRevolution', is its potential competitive edge. Putnamu2019s research capabilities and expertise in the healthcare sector may provide an advantage in identifying promising companies. The focused thematic approach allows investors to target specific growth areas. The fund's competitive edge hinges on its ability to outperform passive or broader biotech ETFs through astute stock picking.
Risk Analysis
Volatility
SYNB is likely to exhibit high volatility due to its focus on growth-oriented companies in the biotechnology sector.
Market Risk
Specific risks associated with SYNB include regulatory risks impacting the biotechnology and healthcare industries, as well as the risk of investing in companies with unproven technologies or products.
Investor Profile
Ideal Investor Profile
The ideal investor for SYNB is someone with a high-risk tolerance and a long-term investment horizon, seeking exposure to the high-growth potential of the BioRevolution.
Market Risk
SYNB is best suited for long-term investors who understand the risks and potential rewards of investing in innovative biotechnology companies.
Summary
The Putnam BioRevolution ETF (SYNB) offers investors exposure to companies at the forefront of biotechnological innovation. Its active management approach allows for flexible stock selection but may result in higher volatility. This ETF is best suited for risk-tolerant investors seeking long-term growth within the 'BioRevolution' sector. Investors should consider the fund's higher expense ratio and relatively low liquidity. The ETF is competing against well-established funds within the market.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Putnam Investments Website
- SEC Filings
- Financial Data Providers (e.g., Bloomberg, Yahoo Finance)
Disclaimers:
The data provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual circumstances and consultation with a qualified financial advisor. Market share data and performance figures may vary depending on the source and date of analysis.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Putnam Biorevolution ETF
Exchange NYSE ARCA | Headquaters - | ||
IPO Launch date - | CEO - | ||
Sector - | Industry - | Full time employees - | Website |
Full time employees - | Website | ||
The fund invests mainly in common stocks (growth or value stocks or both) of companies worldwide of any size with a focus on "biology revolution" companies. From time to time, the fund may invest a significant portion of its assets in companies in one or more related industries or sectors, including the health care, consumer discretionary, consumer staples, biotechnology and materials sectors. The fund is non-diversified.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.